Showing results (331-340 of 348) with videos related to

Sort By:
Pageof 35
International Journal of Chronic Obstructive Pulmonary Disease|April 21, 2020
Serum β2-Microglobulin is Associated with Mortality in Hospitalized Patients with Exacerbated Chronic Obstructive Pulmonary DiseaseWenping Mao, Jing Wang, Liming Zhang, et al.
Journal of Digestive Diseases|February 26, 2024
Differences in the perceptions of patients with primary biliary cholangitis and physicians from various hospital departments: An online surveyYan Sheng Liu, Gui Jia, Da Wei Ding, et al.
Nanophotonics (Berlin, Germany)|December 5, 2024
Noninvasive inset-integrated meta-atom for achieving single-layer metasurface simultaneously with coded microwave reflectivity and digitalized infrared emissivityHui-Ting Sun, Jun Wang, Rui-Chao Zhu, et al.
International Journal of Surgery (London, England)|June 25, 2025
Deep learning algorithms from histopathological images stratify molecular subtypes for leiomyosarcoma: a proof-and-concept diagnostic studyShaohui He, Jun Chen, Yanfang Liu, et al.
Frontiers in Pharmacology|June 17, 2022
Cattle Bile <i>Arisaema</i> Aqueous Extracts Protect Against Febrile Seizures in Rats Through Regulating Neurotransmitters and Suppressing NeuroinflammationFa-Zhi Su, Chen-Xi Bai, Yumeng Luo, et al.
Disease Markers|November 14, 2014
The association between bile salt export pump single-nucleotide polymorphisms and primary biliary cirrhosis susceptibility and ursodeoxycholic acid responseRui-rui Chen, Yuan-jun Li, Xin-min Zhou, et al.
Scientific Reports|October 12, 2021
Effects of Bushen-Tiaojing-Fang on the pregnancy outcomes of infertile patients with repeated controlled ovarian stimulationYu-Cong Ma, Gui-Min Hao, Zhi-Ming Zhao, et al.
Acta Pharmacologica Sinica|September 18, 2024
SGLT2 inhibitors ameliorate NAFLD in mice via downregulating PFKFB3, suppressing glycolysis and modulating macrophage polarizationXia-Fang Lin, Xiao-Na Cui, Jin Yang, et al.
Breast Cancer Research and Treatment|August 2, 2019
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancerVandana G Abramson, Mafalda Oliveira, Andrés Cervantes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2018
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast CancerMaura N Dickler, Cristina Saura, Donald A Richards, et al.
Pageof 35